Table 2

 Details of interventions used and outcomes measured in the 16 randomised critical care studies (reported in 18 articles) included in meta-analysis. Further study information available in online data supplement

StudyCharacteristics of fluid treatment interventionsOutcomes
Albumin (%)Control fluid(s)Intervention period (days)Daily albumin dose (g)Mean (SD) serum albumin level ≤24 hours after intervention (g/L)Final mortality observation (days)% baseline mortality, v (a) control, (b) crystalloid, (c) HES, (d) gelatin% observed power v (a) control, (b) crystalloid, (c) HES, (d) gelatin
ALBIOS 20143820; predefined doseCrystalloid9*24.228.6 (5.4)90(a) 42.9(a) 18.5
Boldt et al 19957520; variable doseColloid (HES†)570ICU(a) 66.7(a) 1.1
Boldt, Heesen, et al 19967420‡; variable doseColloid (HES†)584.4ICU(a) 26.7(a) 5.5
Boldt, Müller, et al 19967620; variable doseColloid (HES†)571.6ICU(a) 35.7(a) 5.6
Boldt, Muller, et al 19967720; variable doseColloid (HES†)5101ICU(a) 21.4(a) 22.2
Dolecek et al 20097820§; predefined doseColloid (HES¶)34028(a) 13.3(a) 15.4
EARSS 20113720**; predefined doseCrystalloid (0.9% saline)360~2490(a) 35.1(a) 2.3
Friedman et al 2008794††; predefined doseColloid (HES‡‡)0.0316Hospital(a) 37(a) 3.9
Haupt et al 1982805§§; variable doseCrystalloid (0.9% saline§§); colloid (HES¶¶)1155***Hospital(a) 61.5, (b) 75.0, (c) 50.0(a) 5.9, (b) 2.4, (c) 11.5
Metildi et al 1984815; variable doseCrystalloid (Ringer’s lactate)285***Hospital(a) 91.7(a) 8.7
Palumbo et al 20068220; variable doseColloid (HES¶)—; 5—; 5(a) 30(a) 6.4
Rackow et al 1983835§§; variable doseCrystalloid (0.9% saline§§); colloid (HES¶¶)1141***Hospital(a) 60.0, (b) 75.0, (c) 50.0(a) 10.3, (b) 2.4, (c) 17.9
Rackow et al 1989845§§; variable doseColloid (HES†††)0.0349Hospital(a) 50(a) 1.1
SAFE 20047, 201184‡‡‡; variable doseCrystalloid (0.9% saline)8.231.7~2628(a) 35.3(a) 40
Van der Heijden et al 200986, Trof et al 2010855§§§; variable doseCrystalloid (0.9% saline); colloids (HES¶¶¶; gelatin****)0.0630027 (3)ICU(a) 38.9, (b) 33.3, (c) 50.0, (d) 33.3(a) 2.3, (b) 1.1, (c) 8.0, (d) 1.1
Veneman et al 20048720††††; predefined doseCrystalloid (0.9% saline); colloid (HES‡‡‡‡)36030(a) 56(a) 4.6

SD=standard deviation; ICU=intensive or critical care unit; HES=hydroxyethyl starch; — =value unclear or not reported; ~ =value estimated from a graph.

* ≤28 days, median presented.

† 10% pentastarch 200 kDa.

‡ Sartorius membrane 20 kDa.

§ Immuno, Baxter.

¶ 6% tetrastarch 130 kDa (Voluven, Fresenius-Kabi).

** Vialebex, LFB.

†† Red Cross of Belgium.

‡‡ 6% or 10% pentastarch 200 kDa (HAES-steril; Fresenius).

§§ Cutter.

¶¶ 6% hetastarch (Hespan, American Critical Care).

*** Data from study population.

††† 10% pentastarch (Dupont Critical Care).

‡‡‡ Albumex, CSL.

§§§ Cealb, Sanquin.

¶¶¶ 6% pentastarch 200 kDa.

**** 4% gelatin (Gelofusin, Braun Medical, Melsungen AG).

†††† CLB.

‡‡‡‡ 10% HES (Fresenius).